---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-065806"
form_type: "8-K"
ticker: "MIST"
cik: "0001408443"
company_name: "Milestone Pharmaceuticals Inc."
filed_at: "2024-05-29T23:59:59+00:00"
generated_at: "2026-06-01T07:38:23.772654+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Milestone Pharma gets FDA NDA acceptance for CARDAMYST (etripamil) nasal spray for PSVT

## Summary
- FDA accepted NDA on May 26, 2024 for CARDAMYST (etripamil) nasal spray for paroxysmal supraventricular tachycardia (PSVT).
- PDUFA target date set at 10 months from acceptance (approx. March 2025).
- CEO Joseph Oliveto cites progress toward a new self-administered treatment option for PSVT patients.
- CARDAMYST clinical program represents the largest data package ever studied for acute self-management of PSVT.
- Brand name CARDAMYST is conditionally approved by FDA; commercial preparations continue for potential launch.

## SEC filing metadata
- accession: 0001104659-24-065806
- form_type: 8-K
- ticker: MIST
- cik: 0001408443
- company_name: Milestone Pharmaceuticals Inc.
- filed_at: 2024-05-29T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1408443/000110465924065806/0001104659-24-065806-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1408443/000110465924065806/tm2415708d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-065806
- JSON: https://secwatch.observer/filing/0001104659-24-065806.json
- Plain text: https://secwatch.observer/filing/0001104659-24-065806.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.